medigraphic.com
ISSN 0210-5187 (Electronic)

2005, Number 3

<< Back Next >>

Med Cutan Iber Lat Am 2005; 33 (3)

Pimecrolimus and UVB narrow band (311 nm) phototherapy in vitiligo

Zurita G, Galán R, Ochoa E, Uraga E

Language: Spanish
References: 13
Page: 103-107
PDF size: 425.31 Kb.


ABSTRACT

On account of therapeutic combinations tending to lead to a synergism, we associated pimecrolimus and UVB 311 phototherapy in the treatment of vitíligo Twenty-one patients were recruited. The depigmentation median before treatment was 32± 4%. vs15±3% post-treament. (Wilcoxon p=0.0001) The repigmentatin median was 51±25%. The median UVB accumulated dose was 16± 11 Joules/cm2, with a median 29±15 sessions, and a median duration of treatment of 4±2 month. At the study’s start, 80 percent of patients had a VIDA= 4 to 3. After treatment, 42 percent had a VIDA=0 to 1. Our therapeutic combination shortened duration of treatment, and used lower accumulated UVB doses than previously reported. It was also efficacious as a disease-stabilizer among a significat percentage of patients


REFERENCES

  1. Fitzpatrick TB. Mechanisms of phototherapy in vitiligo. Arch 1997;133:1591-2

  2. Njoo MD, Spuis Pl, Boss JD, Westerhof W, Bussuyt Pm. Nonsurgical repigmentation teherapies in vitiligo. Meta-anŕlisis of the literature. Arch Dermatol, 1998;134:1532-40

  3. Westerhof W, Nieuweboer-Krobotova L. Treatment of Vitiligo with UVB radiation vs Topical Psoraleno Plus UV-A. Arch Dermatol. 1997;133:1591-2

  4. Wellintong K, Jarvis B. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs 2002;62:817-40

  5. Tanghetti E. Tacrolimus oitment 0.1% produces repigmentation in patients with vitiligo: Results of a prospective patient series. Cutis 2003;71:158- 62

  6. Njoo MD, Spuis Pl, Boss JD, Westerhof W, Bussuyt Pm. Nonsurgical repigmentation teherapies in vitiligo. Arch Dermatol, 1998;14:196 -201

  7. Ermis O, Alposy E, Getin L, Yilmaz E. Is the efficacy of psoraleno plus ultraviolet A therapy for vitiligo enhanced by current topical calcipotriol . a placebo controlled double-blind study. Br. J Dermatol, 2001;145:472-5

  8. Assman T, Homey B, Ruziicka T Application of tacrolimus for the treatment skin disorders. Inmunopharmacology. 2000;47:203-13

  9. Lepe V, Moncada Benjamín, Castanedocazares JP, Torres-Alvarez MB, Ortiz C, Torres-Rubalcava A. A doule-blind randomized trial of 0.1% Tacroloimus vs 0.005% clobetasol for the tratment of chilhood vitiligo. Arch Dermatol. 2003; 139:581-4

  10. Mayoral F, Gonzales C, Shah N, Arciniegas C. Repigmentation of vitiligo with Pimecrolimus: A case report. Dermatol 2003;207:322-3

  11. Roelandts R. Photo(chemo) therapy for vitiligo. Photodermatol Photoinmmunol Photomed. 2003;19:1-4

  12. Njoo M.D, Bos J.D, Westerhof W. Treatment of generalized vitiligo in children with narrow band (TL01) UVB radiation therapy. J Am Acad Dermatol 2000;4:1-12

  13. Koster W, Wiskemann A. Phototherapy mit UVB bei Vitiligo. Z Hautkr 1990;65:1022-9




2020     |     www.medigraphic.com